http://orcid.org/0000-0002-9348-466X
References
- Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012;12:564–571.
- Chun K-S, Kundu J, Kundu JK, et al. Targeting NRF2-KEAP1 signaling for chemoprevention of skin carcinogenesis with bioactive phytochemicals. Toxicol Lett. 2014;229:73–84.
- Leinonen HM, Kansanen E, Pölönen P, et al. Role of the KEAP1-NRF2 pathway in cancer. Adv Cancer Res. 2014;122:281–320.
- Hast BE, Goldfarb D, Mulvaney KM, et al. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination. Cancer Res. 2013;73:2199–2210.
- Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the KEAP1–NRF2 pathway in stress response and cancer evolution. Genes Cells. 2011;16:123–140.
- Glynn IM. A hundred years of sodium pumping. Annu Rev Physiol. 2002;64:1–18.
- Kaplan JH. Biochemistry of Na,K-ATPase. Annu Rev Biochem. 2002;71:511–535.
- Geering K. Functional roles of Na,K-ATPase subunits. Curr Opin Nephrol Hypertens. 2008;17:526–532.
- Bagrov AY, Shapiro JI, Fedorova OV. Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev. 2009;61:9–38.
- Babula P, Masarik M, Adam V, et al. From Na+/K+-ATPase and cardiac glycosides to cytotoxicity and cancer treatment. AntiCancer Agents Med Chem. 2013;13:1069–1087.
- Choi E-J, Jung B-J, Lee S-H, et al. A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer. Oncogene. 2017;36:5285–5295.
- Keum YS, Choi BY. Molecular and chemical regulation of the KEAP1-NRF2 signaling pathway. Molecules. 2014;19:10074–10089.
- Hayes JD, Chowdhry S, Dinkova-Kostova AT, et al. Dual regulation of transcription factor NRF2 by KEAP1 and by the combined actions of beta-TrCP and GSK-3. Biochm Soc Trans. 2015;43:611–620.
- Chowdhry S, Zhang Y, McMahon M, et al. NRF2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene. 2013;32:3765–3781.
- Bai X, Chen Y, Hou X, et al. Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab Rev. 2016;48:541–567.
- Prassas I, Diamandis EP. Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov. 2008;7:926–935.
- Schneider N, Cerella C, Simões CMO, et al. Anticancer and immunogenic properties of cardiac glycosides. Molecules. 2017;22:1932.
- Yang SY, Kim NH, Cho YS, et al. Convallatoxin, a dual inducer of autophagy and apoptosis, inhibits angiogenesis in vitro and in vivo. Plos One. 2014;9:e91094.
- Epstein FH, Smith TW. Digitalis. Mechanisms of action and clinical use. N Engl J Med. 1988;318:358–365.